Bevacizumab may differentially improve ovarian cancer outcome in patients with proliferative and mesenchymal molecular subtypes

DASL gene expression arrays were performed on FFPE tissue from patients enrolled on the ICON7 trial. Patients were stratified into four TCGA molecular subtypes. DASL gene expression arrays were performed on FFPE tissue from patients enrolled on the ICON7 trial. Patients were stratified into four TCGA molecular subtypes. Associations between molecular subtype and the efficacy of randomly assigned therapy with bevacizumab were assessed. Standard treatment: CARBOPLATIN PLUS PACLITAXEL CHEMOTHERAPY Bevacizumab treatment: CARBOPLATIN PLUS PACLITAXEL CHEMOTHERAPY PLUS BEVACIZUMAB The primary endpoints in the ICON7 trial used to measure treatment efficacy were OS and PFS. OS: Overall survival was calculated from the date of randomization to the date of death from any cause; data for patients still alive were censored at the date the patient was last known to be alive. final_ostm = time in days final_osid = 1=dead, 0=alive PFS: Progression-free survival was calculated from the date of randomization to the date of the first indication of disease progression or death, whichever occurred first; the data for patients who were alive without disease progression were censored as of the date of their last assessment. final_pfstm = time in days final_pfsid = 1=event, 0=no-event